Relates to prescribing opioids to a minor; prohibits practitioners from prescribing to a minor more than a seven day supply of any controlled substance containing an opioid; requires practitioners to obtain written parental consent before issuing a first prescription of a controlled substance containing an opioid to a minor; establishes exceptions.
S00732 would add a new section to the Public Health Law governing when practitioners may prescribe controlled substances containing opioids to minors. In general, it would prohibit prescribing more than a seven-day supply to a minor and would require, before the first prescription in a course of treatment, that the practitioner assess the minor’s mental health and substance use history, discuss opioid-related risks with the minor and a parent or other authorized adult, and obtain written consent on a form prescribed by the commissioner. The required discussion would include addiction and overdose risks, heightened risk for patients with mental health or substance use disorders, and the dangers of combining opioids with benzodiazepines, alcohol, or other central nervous system depressants.
The bill also creates exceptions and special rules. The consent and counseling requirements would not apply in a medical emergency or when the practitioner determines that compliance would be detrimental to the minor’s health or safety. If consent is given by an adult other than a parent or guardian who is authorized to consent to treatment, the prescription would be limited to a single 72-hour supply. Signed consent forms would have to be kept in the minor’s medical record, and the bill would take effect 90 days after becoming law, with immediate authorization for implementing regulations.
Its impact on state law would be to impose new prescribing limits and documentation requirements on opioid prescriptions for minors in New York, adding a layer of parental or authorized-adult involvement and formal risk counseling to the existing medical prescribing framework. It would affect physicians, nurse practitioners, physician assistants, pharmacists, minors receiving opioid treatment, and parents or other adults authorized to consent to care, while also requiring the Department of Health to create a consent form and potentially related rules.
The available context shows no recorded committee debate or votes, so there is no documented legislative sentiment from hearings or floor action. Based on the bill’s structure, it appears to reflect a public-health and opioid-abuse-prevention approach, emphasizing caution, informed consent, and limits on access for minors. Because there is no transcript or vote history, no specific supporters or opponents are identified in the record provided.
The main points of contention likely concern whether the bill’s consent and supply limits could delay pain treatment for minors, especially in urgent or complex cases, versus whether the safeguards are necessary to reduce misuse, addiction, and overdose risk. The bill’s exceptions for emergencies and for situations where compliance would harm the minor suggest an attempt to balance those concerns, but the requirement for written consent and the shorter 72-hour limit when a non-parent authorizes treatment could still be viewed as burdensome by some providers or families.
The bill would amend the New York Public Health Law by creating a new section regulating opioid prescribing to minors. It would establish a seven-day maximum supply for controlled substances containing opioids, require pre-prescription counseling and written consent for a minor’s first opioid prescription in a treatment course, and mandate recordkeeping of the signed consent form. It would also require the Department of Health to develop a prescribed consent form and allow implementing regulations to be prepared before the effective date.
No committee transcript or vote record is provided, so there is no direct evidence of legislative debate or recorded support/opposition. The bill’s design indicates a generally precautionary, anti-opioid sentiment focused on protecting minors from addiction and overdose while preserving exceptions for emergencies and clinical judgment.
The likely areas of contention are the added administrative and consent requirements, the seven-day supply cap, and the potential for delays or barriers to pain management for minors. Supporters would likely emphasize opioid misuse prevention, parental awareness, and informed consent, while critics may argue that the bill could complicate legitimate treatment, especially where a parent is unavailable or where a longer course is medically appropriate. The exception for emergencies and for situations where compliance would be harmful appears intended to address these concerns, but the balance between access and restriction remains the central issue.